Learn More
Biogenex Laboratories PR (Insite) : PR88: 1mL

Supplier: Biogenex Laboratories MU328UC
The use of monoclonal antibodies to determine progesterone receptor status increases the predictive value of immunohistochemical analysis with respect to the response of human tumors to hormonal modulation. Historically, estrogen receptor-positive/progesterone receptor-positive breast carcinoma patients have demonstrated a better response to endocrine therapy than estrogen receptor-positive/ progesterone receptor-negative patients.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.